Compare Becton Dickinson and Co (BDX) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Tesla, Inc. — how do they compare? Becton Dickinson and Co trades at $156.39 (market cap $41.51B), while Tesla, Inc. trades at $397.41 (market cap $1.49T). The key difference: Tesla, Inc. is far larger — about 35.9× Becton Dickinson and Co's market cap, and Becton Dickinson and Co pays a 2.79% dividend while Tesla, Inc. pays none. Which is the better fit depends on your goals.
| BDX | TSLA | |
|---|---|---|
Market Cap | $41.51B | $1.49T |
Sector | Health | Consumer Cyclical |
52-Week High | $185.39 | $489.88 |
52-Week Low | $135.49 | $302.63 |
Enterprise Value | $57.97B | $1.46T |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
Tesla (TSLA) trades at $396.87, up 0.53% with mixed technical signals showing bearish moving averages but neutral oscillators. The company faces valuation challenges with a P/E ratio of 363.47 and declining profit margins, though recent earnings beat expectations in Q1 2026. Positive developments include regulatory approval for self-driving software in Europe and strong growth in German registrations.
Tesla's outlook balances innovation potential against execution risks. The stock offers exposure to autonomous driving leadership and energy growth, but faces intense EV competition and margin pressure. Analyst consensus price target of $409.26 suggests modest upside, though institutional sentiment remains divided with 39.5% buy ratings versus 18.5% sell recommendations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
